The antiatherogenic potential of blocking the renin-angiotensin system

Bibliography

• THE SOLVD INVESTIGATORS: Effect of enalapril on sur-vival in patients with reduced left ventricular ejection fractions and congestive heart failure. New Engl. J. Med. (1991) 325:293–302.
   PubMed Web of Science ®Google Scholar
• THE SOLVD INVESTIGATORS: Effect of enalapril on mor-tality and the development of heart failure in asympto-matic patients with reduced left ventricular ejection fractions. New Engl. J. Med. (1992) 327:685–691.
   PubMed Web of Science ®Google Scholar
• YUSUF S, PEPINE CJ, GARCES C et al.: Effect of enalapril on myocardial infarction and unstable angina in pa-tients with low ejection fractions. Lancet (1992) 340:1173–1178.
   PubMed Web of Science ®Google Scholar
• FRANCIS GS, BENEDICT C, JOHNSTONE DE et al.: Com-parison of neuroendocrine activation in patients with left ventricular dysfunction with and without conges-tive heart failure. Circulation (1990) 82:1724–1729.
   PubMed Web of Science ®Google Scholar
• BRUNNER HR, GAVRAS H, WAEBER B et al.: Oralangiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann. Intern. Med. (1979) 90:19–23.
   PubMed Web of Science ®Google Scholar
• NIARCHOS AP, PICKERING TG, WALLACE JM, CASE DB, LA-RAGH JH: Hemodynamic effects of the converting en-zyme inhibitor teprotide in normal- and high-renin hypertension. Clin. Pharmacol Ther. (1980) 28:592–601.
   PubMed Web of Science ®Google Scholar
• COHEN ML, KURZ KD: Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421. J. Phar-macol. Exp. Ther. (1982) 220:63–69.
   PubMed Web of Science ®Google Scholar
• NAKATA K, NISHIMURA K, TAKADA T et al: Effects of anangiotensin-converting enzyme (ACE) inhibitor, SA446, on tissue ACE activity in normotensive, sponta-neously hypertensive, and renal hypertensive rats. J. Cardiovasc. Pharmacol. (1987) 9:305–310.
   PubMed Web of Science ®Google Scholar
• UNGER T, GANTEN D, LANG RE, SCHOELKENS BA: Persis-tent tissue converting enzyme inhibition following chronic treatment with 11oe498 and MK421 in sponta-neously hypertensive rats. J. Cardiovasc. Pharmacol. (1985) 7:36–40.
   PubMed Web of Science ®Google Scholar
• ASAAD MM, ANTONACCIO MJ: Vascular wall renin in spontaneously hypertensive rats: potential relevance to hypertension maintenance and antihypertensive ef-fect of captopril. Hypertension (1982) 4:487–493.
   PubMed Web of Science ®Google Scholar
• PAUL M, WAGNER J, DZAU VJ: Gene expression of the renin-angiotensin system in human tissues. J. Clin. In-vest. (1993) 91:2058–2064.
   PubMed Web of Science ®Google Scholar
• OKUNISHI H, MIYAZAKI M, TODA N: Evidence for a puta-tively new angiotensin 11-generating enzyme in the vas-cular wall. J. Hypertens. (1984) 2:277–284.
   PubMedGoogle Scholar
• ROSENTHAL J, THURNREITER M, PLASCHKE M et al.:Renin-like enzymes in human vasculature. Hypertension (1990) 15:848–853.
   PubMed Web of Science ®Google Scholar
• URATA H, BOEHM KD, PHILIP A et al.: Cellular localiza-tion and regional distribution of an angiotensin II-forming chymase in the heart. J. Clin. Invest. (1993) 91 :1269–1281.
   PubMed Web of Science ®Google Scholar
• SEALEY JE, ATLAS SA, LARAGH JH: Prorenin and otherlarge molecular weight forms of renin. Endocrinol. Rev. (1980) 1:365–391.
   PubMedGoogle Scholar
• LOUDON M, BING RF, THURSTON H, SWALES JD: Arterial wall uptake of renal renin and blood pressure control. Hypertension (1983) 5:629–634.
   PubMed Web of Science ®Google Scholar
• DANSER AHJ, DE LANNOY LM, SCHOEMAKER RM et al.: Renin-angiotensin system components in cardiac in-terstitial fluid, uptake from plasma and local produc-tion. Circulation (1994) 90\(Suppl. 1):342.
   Google Scholar
• KATO H, IWAI N, INUI H et al: Regulation of vascular angiotensin release. Hypertension (1993) 21:446–454.
   PubMed Web of Science ®Google Scholar
• LINDPAINTNER K, JIN M, NIEDERMAIER N, WILHELM MJ, GANTEN D: Cardiac angiotensinogen and its local acti-vation in the isolated perfused beating heart. Circ. Res. (1990) 67:564–573.
   PubMed Web of Science ®Google Scholar
• VICAUT E, HOU X: Arteriolar constriction and local renin-angiotensin system in rat microcirculation. Hy-pertension (1993) 21:491–497.
   PubMed Web of Science ®Google Scholar
• DANSER AHJ, VAN KATS JP, ADMIRAAL PJJ et al.: Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension (1994) 24:37–48.
   Google Scholar
• •Exemplary study on the interaction between tissue and endo-crine RAS.
   Google Scholar
• FORDIS CM, MEGORDEN JS, ROPCHAK TG, KEISER HR: Ab-sence of renin-like activity in rat aorta and microves-sels. Hypertension (1983) 5:635–641.
   PubMed Web of Science ®Google Scholar
• BAKER KM, CHERNIN MI, WIXSON SK, ACETO JF: Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am. J. Physiol. (1990) 259:H324–H332.
   PubMed Web of Science ®Google Scholar
• MORISHITA R, HIGAKI J, MIYAZAKI M, OGIHARA T: Possi-ble role of the vascular renin-angiotensin system in hy-pertension and vascular hypertrophy. Hypertension (1992) 19 (Suppl. II): 62–67.
   Google Scholar
• OKAMURA T, MIYAZAKI M, INAGAMI T, TODA N: Vascularrenin-angiotensin system in two-kidney, one clip hy-pertensive rats. Hypertension (1986) 8:560–565.
   PubMed Web of Science ®Google Scholar
• IWAI N, IZUMI M, INAGAMI T, KINOSHITA M: Induction ofrenin in medial smooth muscle cells by balloon injury. Hypertension (1997) 29:1044–1050.
   PubMed Web of Science ®Google Scholar
• •First study monitoring the mRNA expression of all the RAS components during the atherosclerotic response to vessel wall injury.
   Google Scholar
• RAKUGI H, WANG DS, DZAU VJ, PRATT RE: Potential importance of tissue angiotensin-converting enzyme in-hibition in preventing neointima formation. Circulation (1994) 90:449–455.
   PubMed Web of Science ®Google Scholar
• •An interesting study demonstrating a correlation between lo-cal ACE activity and the degree of neointimal hyperplasia.
   Google Scholar
• SHIOTA N, OKUNISHI H, FUKAMIZU A eta].: Activation of two angiotensin-generating systems in the balloon-injured artery. FEBS (1993) 323:239–242.
   Google Scholar
• VAN LEEUWEN RT, KOL A, ANDREOTTI F et al.: Angio-tensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messen-ger RNA in cultured rat aortic smooth muscle cells. Cir-culation (1994) 90:362–368.
   PubMed Web of Science ®Google Scholar
• FEENER EP, NORTHRUP JM, AIELLO LP, KING GL: Angio-tensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth mus-cle cells. J. Clin. Invest. (1995) 95:1353–1362.
   PubMed Web of Science ®Google Scholar
• GRAEFE M, AUCH-SCHWELK W, GRAF K et al.: Induction of the adhesion molecule E-selectin in human cardiac endothelial cells by angiotensin II. Circulation (1993) 88(Suppl. I): 316.
   Google Scholar
• HERNANDEZ-PRESA M, BUSTOS C, ORTEGO M et al.: Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macro-phage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation (1997) 95:1532–1541.
   PubMed Web of Science ®Google Scholar
• WILLIAMS B, BAKER AQ, GALLACHER B, LODWICK D: Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension (1995) 25:913–917.
   PubMed Web of Science ®Google Scholar
• DUBEY RK, ROY A, OVERBECK HW: Culture of renal arte-riolar smooth muscle cells. Mitogenic responses to angiotensin II. Circ. Res. (1992) 71:1143–1152.
   Google Scholar
• PAQUET JL, BAUDOUIN-LEGROS M, BRUNELLE G, MEYER P: Angiotensin ffinduced proliferation of aortic myo-cytes in spontaneously hypertensive rats. J. Hypertens. (1990) 8:565–572.
   PubMed Web of Science ®Google Scholar
• GRIENDLING KK, MINIERI CA, OLLERENSHAW JD, ALEX-ANDER RW: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. (1994) 74:1141–1148.
   PubMed Web of Science ®Google Scholar
• OSTERRIEDER W, MUELLER RKM, POWELL JS et al: Role of angiotensin II in injury-induced neointima formation in rats. Hypertension (1991) 18 (Suppl.
   Google Scholar
• HAMDAN AD, QUIST WC, GAGNE JB, FEENER EP: Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation (1996) 93:1073–1078.
   PubMed Web of Science ®Google Scholar
• CAMPELL DJ, KLADIS A, DUNCAN A: Effects of converting enzyme inhibitors on angiotensin and bradykinin pep-tides. Hypertension (1994) 23:439–449.
   PubMed Web of Science ®Google Scholar
• A detailed analysis on the effects of ACE inhibitors on circu-lating and tissue levels of angiotensin and bradykinin pep-tides.
   Google Scholar
• FARHY RD, CARRETERO OA, HO KL, SCICLI AG: Role of kinins and nitric oxide in the effects of angiotensin con-verting enzyme inhibitors on neointima formation. Circ. Res. (1993) 72:1202–1210.
   PubMed Web of Science ®Google Scholar
• AUCH-SCHWELK W, BOSSALLER C, CLAUS M et al: ACE in-hibitors are endothelium dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin. Cardiovasc. Res. (1993) 27:312–317.
   PubMed Web of Science ®Google Scholar
• MOMBOULI JV, ILLIANO S, NAGAO T, SCOTT-BURDEN T, VANHOUTTE PM: Potentiation of endothelium-dependent relaxations to bradykinin by angiotensin I converting enzyme inhibitors in canine coronary ar-tery involves both endothelium-derived relaxing and hyperpolarizing factors. Circ. Res. (1992) 71:137–144.
   PubMed Web of Science ®Google Scholar
• MOMBOULI JV, VANHOUTTE PM: Kinins mediate kallikrein-induced endothelium-dependent relaxa-tions in isolated canine coronary arteries. Biochem. Bio-phys. Res. Commun. (1992) 185:693–697.
   PubMed Web of Science ®Google Scholar
• SCHINI VB, BOULANGER C, REGOLI D, VANHOUTTE PM:Bradykinin stimulates the production of cyclic GMP via activation of B2-kinin receptors in cultured porcine aortic endothelial cells. J. Pharmacol. Exp. Ther. (1990) 252:581–585.
   PubMed Web of Science ®Google Scholar
• WIEMER G, SCHOELKENS BA, BECKER RMA, BUSSE R: Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bra-dykinin. Hypertension (1991) 18:558–563.
   PubMed Web of Science ®Google Scholar
• ZICHE M, PARENTI A, LEDDA F et al.: Nitric oxide pro-motes proliferation and plasminogen activator produc-tion by coronary venular endothelium through endogenous bFGF. Circ. Res. (1997) 80:845–852.
   PubMed Web of Science ®Google Scholar
• RADOMSKI MW, PALMER RMJ, MONCADA S: Endogenous nitric oxide inhibits human platelet adhesion to vascu-lar endothelium. Lancet (1987) 2:1057–1058.
   PubMed Web of Science ®Google Scholar
• FREEDMAN JE, LOSCALZO J, BARNARD MR et al: Nitric ox-ide released from activated platelets inhibits platelet re-cruitment. J. Clin. Invest. (1997) 100:350–356.
   PubMed Web of Science ®Google Scholar
• BARRETT ML, WILLIS AL, VANE JR: Inhibition of platelet-derived mitogen release by nitric oxide (EDRF). Agents Actions (1989) 27:488–491.
   PubMedGoogle Scholar
• DE CATERINA R, LIBBY P, PENG H et al: Nitric oxide de-creases cytokine-induced endothelial activation. J. Clin. Invest. (1995) 96:60–68.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI M, IKEDA U, MASUYAMA J et al: Nitric oxideattenuates adhesion molecule expression in human en-dothelial cells. Cytokine (1996) 8:817–821.
   PubMedGoogle Scholar
• ZEIHER AM, FISSLTHALER B, SCHRAY-UTZ B, BUSSE R: Ni-tric oxide modulates the expression of monocyte che-moattractant protein 1 in cultured human endothelial cells. Circ. Res. (1995) 76:980–986.
   PubMed Web of Science ®Google Scholar
• GARG UC, HASSID A: Nitric oxide-generating vasodila-tors and 8-bromo-cyclic guanosine monophosphate in-hibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest. (1989) 83:1774–1777.
   PubMed Web of Science ®Google Scholar
• VON DER LEYEN HE, GIBBONS GH, MORISHITA R et al: Gene therapy inhibiting neointimal vascular lesion - in vivo transfer of endothelial cell nitric oxide synthase gene. Proc. Natl. Acad. Sci. USA (1995) 92:1137–1141.
   PubMed Web of Science ®Google Scholar
• DUBEY RK, JACKSON EK, LUESCHER TF: Nitric oxide in-hibits angiotensin ffinduced migration of rat aortic smooth muscle cell. J. Clin. Invest. (1995) 96:141–149.
   PubMed Web of Science ®Google Scholar
• RUBANYI GM, HO EH, CANTOR EH, LUMMA WC, BO-TELHO LHP: Cytoprotective function of nitric oxide: in-activation of superoxide radicals produced by human leukocytes. Biochem. Biophys. Res. Commun. (1991) 181:1392–1397.
   PubMed Web of Science ®Google Scholar
• KANNER J, HAREL S, GRANIT R: Nitric oxide, an inhibitor of lipid oxidation by lipoxygenase, cyclooxygenase and hemoglobin. Lipids (1992) 27:46–49.
   PubMed Web of Science ®Google Scholar
• HECKER M, POERSTI I, BARA AT, BUSSE R: Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the re-ceptor level. Br. J. Pharmacol (1994) 111:238-244. Compelling demonstration of a new aspect of the mechanism underlying the action of ACE inhibitors.
   Google Scholar
• SANTOS RAS, BROSNIHAN KB, JACOBSEN DW, DICOR-LETO PE, FERRARIO CM: Production of angiotensin-(1–7) by human vascular endothelium. Hypertension (1992) 19 (Suppl II): 56–61.
   Google Scholar
• JAISWAL N, DIZ DI, CHAPPELL MC, KHOSLA MC, FERRARIOCM: Stimulation of endothelial cell prostaglandin pro-duction by angiotensin peptides. Hypertension (1992) 19 (Suppl. II): 49–55.
   Google Scholar
• SEYEDI N, XU XB, NASJLETTI A, HINTZE TH: Coronary ki-nin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension (1995) 26:164–170.
   PubMed Web of Science ®Google Scholar
• BROSNIHAN KB, LI P, FERRARIO CM: Angiotensin-(1-7)dilates canine coronary arteries through kinins and ni-tric oxide. Hypertension (1996) 27:523–528.
   PubMed Web of Science ®Google Scholar
• FREEMAN EJ, CHISOLM GM, FERRARIO CM, TALLANT EA:Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension (1996) 28:104–108.
   PubMed Web of Science ®Google Scholar
• TIMMERMANS PBMWM, WONG PC, CHIU AT et al: Angio-tensin II receptors and angiotensin II receptor antago-nists. Pharmacol. Rev. (1993) 45:205–251.
   PubMed Web of Science ®Google Scholar
• BUNKENBURG B, VAN AMELSVOORT T, ROGG H, WOODJM: Receptor-mediated effects of angiotensin II on growth of vascular smooth muscle cells from spontane-ously hypertensive rats. Hypertension (1992) 20:746–754.
   PubMed Web of Science ®Google Scholar
• RAJAGOPALAN S, KURZ S, MUENZEL T et al: Angiotensinffmediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J. Clin. Invest. (1996) 97:1916–1923.
   PubMed Web of Science ®Google Scholar
• KAUFFMAN RF, BEAN JS, ZIMMERMAN KM, BROWN RF,STEINBERG MI: Losartan, a nonpeptide angiotensin II (ang II) receptor antagonist, inhibits neointima forma-tion following balloon injury to rat carotid arteries. Life Sci. (1991) 49:223–228.
   Google Scholar
• JANIAK P, PILLON A, PROST JF, VILAINE JP: Role of angio-tensin subtype 2 receptor in neointima formation after vascular injury. Hypertension (1992) 20:737–745.
   PubMed Web of Science ®Google Scholar
• HUCKLE WR, DRAG MD, ACKER WR et al.: Effects of subtype-selective and balanced angiotensin II receptor antagonists in a porcine coronary artery model of vas-cular restenosis. Circulation (1996) 93:1009–1019.
   PubMed Web of Science ®Google Scholar
• WIEMER G, FINK E, KORTH P et al.: Blockade of ang II(subtype ATI) receptors induces kinin and prostacyclin release from isolated perfused rat hearts. Hypertension (1994) 24 (Suppl. D:396.
   Google Scholar
• •First demonstration of an unexpected yet potentially anti-atherogenic effect of ATI receptor antagonists.
   Google Scholar
• KORTH P, FINK E, LINZ W et al.: Angiotensin II receptorsubtype-stimulated formation of endothelial cyclic GMP and prostacyclin is accompanied by an enhanced release of endogenous kinins. Pharm. Pharmacol Lett. (1995) 5:124–127.
   Google Scholar
• GOETZ RM, KUCH M, HOLTZ J: Chronic nonhypotensivetreatment by angiotensin receptor type-1 antagonists in hypertensive rats restores depressed endothelium-mediated dilation. Eur. Heart J. (1993) 14 (Abstract Suppl.): 387.
   Google Scholar
• VACHER E, RICHER C, GIUDICELLI JF: Effects of losartan on cerebral arteries in stroke-prone spontaneously hy-pertensive rats. J. Hypertens. (1996) 14:1341–1348.
   PubMed Web of Science ®Google Scholar
• SWANSON GN, HANESWORTH JM, SARDINIA MF et al.: Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Reg. Peptides (1992) 40:409–419.
   PubMed Web of Science ®Google Scholar
• •First report of a non-ATi, non-AT2 receptor and its tissue dis-tribution.
   Google Scholar
• CAMPBELL DJ, KLADIS A, VALENTIJN AJ: Effects of losartan on angiotensin and bradykinin peptides, and angiotensin converting enzyme. J. Cardiovasc. Pharma-col. (1995) 26:233–240.
   PubMed Web of Science ®Google Scholar
• •A detailed analysis on the effects of ATi receptor antagonism on circulating and tissue levels of angiotensin and bradykinin peptides.
   Google Scholar
• STOLL M, STECKELINGS UM, PAUL M et al.: The angio-tensin AT2-receptor mediates inhibition of cell prolif-eration in coronary endothelial cells. J. Clin. Invest. (1995) 95:651–657.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA M, HUTCHINSON HG, FUJINAGA M et al.: Growth inhibitory function of type 2 angiotensin II re-ceptor: gain of function study by in vivo gene transfer. Proc. Natl. Acad. Sci. USA (1995) 92:10663–10667.
   PubMed Web of Science ®Google Scholar